Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalities

Combined inhibition of STAT3 and DNA repair in palbociclib-resistant ER-positive breast cancer

(2019) Nicole M. Kettner et al.   CLINICAL CANCER RESEARCH

MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer

(2018) Renée de Leeuw et al.   CLINICAL CANCER RESEARCH

ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment

(2018) Hetal Patel et al.   MOLECULAR CANCER THERAPEUTICS

Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor–positive Breast Cancer

(2018) Chrysiis Michaloglou et al.   MOLECULAR CANCER THERAPEUTICS

The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial

(2018) Ben O'Leary et al.   Cancer Discovery

PaDuA: A Python Library for High-Throughput (Phospho)proteomics Data Analysis

(2018) Anna Ressa et al.   JOURNAL OF PROTEOME RESEARCH

MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer

(2017) Matthew P. Goetz et al.   JOURNAL OF CLINICAL ONCOLOGY

Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance

(2017) Lesley-Ann Martin et al.   Nature Communications

EGFR mediates activation of RET in lung adenocarcinoma with neuroendocrine differentiation characterized by ASCL1 expression

(2017) Kaustubh Bhinge et al.   Oncotarget

Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors

(2016) Shom Goel et al.   CANCER CELL

Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer

(2016) Maria Teresa Herrera-Abreu et al.   CANCER RESEARCH

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

(2016) Gabriel N. Hortobagyi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Palbociclib and Letrozole in Advanced Breast Cancer

(2016) Richard S. Finn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence

(2016) C Yang et al.   ONCOGENE

Targeting WEE1 Kinase in Cancer

(2016) Christopher J. Matheson et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Elucidation of Signaling Pathways from Large-Scale Phosphoproteomic Data Using Protein Interaction Networks

(2016) Jan Daniel Rudolph et al.   Cell Systems

PhosphoPath: Visualization of Phosphosite-centric Dynamics in Temporal Molecular Networks

(2015) Linsey M. Raaijmakers et al.   JOURNAL OF PROTEOME RESEARCH

AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo

(2015) R. Ribas et al.   MOLECULAR CANCER THERAPEUTICS

The history and future of targeting cyclin-dependent kinases in cancer therapy

(2015) Uzma Asghar et al.   NATURE REVIEWS DRUG DISCOVERY

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

(2015) Nicholas C. Turner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of Aromatase Inhibition on Functional Gene Modules in Estrogen Receptor-Positive Breast Cancer and Their Relationship with Antiproliferative Response

(2014) Q. Gao et al.   CLINICAL CANCER RESEARCH

Kinases and Pseudokinases: Lessons from RAF

(2014) A. S. Shaw et al.   MOLECULAR AND CELLULAR BIOLOGY

Targeting transcription regulation in cancer with a covalent CDK7 inhibitor

(2014) Nicholas Kwiatkowski et al.   NATURE

Differences and homologies of chromosomal alterations within and between breast cancer cell lines: a clustering analysis

(2014) Milena Rondón-Lagos et al.   Molecular Cytogenetics

Cyclin D activates the Rb tumor suppressor by mono-phosphorylation

(2014) Anil M Narasimha et al.   eLife

GDNF-RET Signaling in ER-Positive Breast Cancers Is a Key Determinant of Response and Resistance to Aromatase Inhibitors

(2013) A. Morandi et al.   CANCER RESEARCH

Understanding response and resistance to oestrogen deprivation in ER-positive breast cancer

(2013) N. Patani et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Robust phosphoproteome enrichment using monodisperse microsphere–based immobilized titanium (IV) ion affinity chromatography

(2013) Houjiang Zhou et al.   Nature Protocols

AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity

(2011) Sarat Chandarlapaty et al.   CANCER CELL

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Rb inactivation in cell cycle and cancer: The puzzle of highly regulated activating phosphorylation of CDK4 versus constitutively active CDK-activating kinase

(2011) Sabine Paternot et al.   CELL CYCLE

ER -Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer

(2011) T. W. Miller et al.   Cancer Discovery

Functional Viability Profiles of Breast Cancer

(2011) R. Brough et al.   Cancer Discovery

Regulation of cyclin D1 gene expression: Figure 1

(2010) Ini-Isabée Witzel et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Growth factor stimulation induces a distinct ER  cistrome underlying breast cancer endocrine resistance

(2010) M. Lupien et al.   GENES & DEVELOPMENT

ChIP-seq: Using high-throughput sequencing to discover protein–DNA interactions

(2009) Dominic Schmidt et al.   METHODS

Cyclin D1 Expression in Breast Cancer Patients Receiving Adjuvant Tamoxifen-Based Therapy

(2008) M. Rudas et al.   CLINICAL CANCER RESEARCH

AKT Alters Genome-Wide Estrogen Receptor   Binding and Impacts Estrogen Signaling in Breast Cancer

(2008) P. Bhat-Nakshatri et al.   MOLECULAR AND CELLULAR BIOLOGY